

**GLASSIA (alpha<sub>1</sub>-proteinase inhibitor, human) ORDER FORM**

PATIENT NAME: \_\_\_\_\_ DOB: \_\_\_\_\_ WT: \_\_\_\_\_ HT: \_\_\_\_\_

ALLERGIES: \_\_\_\_\_

**DIAGNOSIS**

HAS THE PATIENT PREVIOUSLY RECEIVED: GLASSIA (alpha<sub>1</sub>-PI (human))  NO  YES

BRAND: \_\_\_\_\_ LAST DOSE DATE: \_\_\_\_\_

DIAGNOSIS: \_\_\_\_\_ ICD 10 CODE(S): \_\_\_\_\_

**MEDICATION ORDERS**

**DOSE/FREQUENCY:**

- 60 mg/kg body (actual body weight) IV once weekly (NTE 0.2 mL/kg/min; use 5 micron in-line filter)
- Other: \_\_\_\_\_

Orders are valid for 1 year. For a shorter duration, indicate here: \_\_\_\_\_

**STANDARD IV ORDERS**

**ANCILLARY ORDERS:**

- Infusion Reaction Management per Infusion Solutions Protocol.
- Alteplase 2mg IV to de clot central IV access per Infusion Solutions protocol as needed for occlusion.
- Flush with 0.9% NaCl and/or Heparin 10 u/ml or 100 u/ml per Infusion Solutions protocol.
- Lidocaine 1% - up to 0.2 ml intradermally PRN (may buffer with sodium bicarbonate 8.4% in 10:1 ratio).

**NURSING ORDERS:**

- If no central IV access, RN to insert peripheral IV.
- Obtain weight before each dose
- Monitor vital signs (temp, HR, RR, BP) before therapy, and every 15-30 minutes or with each rate change.
- If an infusion reaction occurs, decrease rate AND monitor vital signs until symptoms subside. If the reaction persists or worsens, stop the infusion, initiate reaction protocol, and notify physician.
- Observe patient for 30 minutes after completion of therapy.

**LABS**

**LAB ORDERS:**

- CBC w/ diff  CRP
- CMP  Other: \_\_\_\_\_

**LAB FREQUENCY:**

- Every dose
- Other: \_\_\_\_\_

**REQUIRED DOCUMENTATION**

**REQUIRED CLINICAL DOCUMENTS:**

- IgA labs (CONTRAINDICATED if patients are IgA deficient with antibodies against IgA)

**RECOMMENDED CLINICAL DOCUMENTS (provide if available):**

- Baseline labs (CBC w/ diff, CMP)

**SUPPORTING DOCUMENTS:**

- Patient demographic and insurance information.
- Copy of front and back of insurance card if available.
- Patient's medication list.
- Supporting clinical notes, including past tried and/or failed therapies.

**PROVIDER INFORMATION**

\_\_\_\_\_  
 PRESCRIBER SIGNATURE (substitution)

\_\_\_\_\_  
 PRESCRIBER SIGNATURE (dispense as written)

\_\_\_\_\_  
 PRINT NAME (FIRST AND LAST)

\_\_\_\_\_  
 DATE